What one share of Neurogene holds
Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression.
Neurogene’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.05 |
|---|---|
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$3.98 |
| Cash and investments | $7.11 |
| Book value | $13.72 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$201.13 | $0.11 | −$119.95 | — | −$846.76 |
| 2013 | — | −$247.58 | $0.18 | −$129.81 | — | −$1,089 |
| 2014 | — | −$13.74 | $0.07 | −$10.15 | — | $16.90 |
| 2015 | — | −$8.65 | $0.01 | −$8.03 | — | $31.50 |
| 2016 | — | −$9.79 | $0.19 | −$8.19 | — | $30.88 |
| 2017 | — | −$10.70 | $0.11 | −$9.64 | — | $21.06 |
| 2018 | — | −$6.71 | $0.01 | −$6.72 | — | $15.44 |
| 2019 | — | −$12.85 | $0.16 | −$3.01 | — | $18.64 |
| 2020 | — | −$3.21 | $0.21 | −$2.58 | — | $22.66 |
| 2021 | — | −$5.51 | $0.30 | −$4.62 | — | −$10.82 |
| 2022 | — | −$5.20 | $0.20 | −$4.98 | — | −$17.02 |
| 2024 | $0.05 | −$4.28 | $0.05 | −$4.07 | — | $20.89 |
| 2025 | $0.00 | −$4.24 | $0.06 | −$3.67 | — | $17.10 |
Common questions about Neurogene
How much does one share of Neurogene earn?
Over the last 12 months, Neurogene lost $5.05 for each share.
Does Neurogene pay a dividend?
Neurogene didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Neurogene’s book value per share?
Neurogene’s book value is $13.72 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Neurogene have?
Each share of Neurogene has $7.11 of cash and investments, as of June 30, 2026.
What is Neurogene’s free cash flow per share?
−$3.98 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Neurogene bought back shares?
Neurogene’s share count rose about 35238% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.